{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:21:50Z","timestamp":1779376910745,"version":"3.53.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019721","name":"Roche Espa\u00f1a","doi-asserted-by":"publisher","award":["SL45180"],"award-info":[{"award-number":["SL45180"]}],"id":[{"id":"10.13039\/100019721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40120-025-00821-y","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:45:18Z","timestamp":1758271518000},"page":"2345-2357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment Preferences of Neurologists in Generalized Myasthenia Gravis: A Conjoint Analysis Study"],"prefix":"10.1007","volume":"14","author":[{"given":"Luis","family":"Querol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"G\u00f3mez-Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Guti\u00e9rrez-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Villaverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tha\u00eds","family":"Armangu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"D\u00edaz-Ab\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Rebollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f2nica","family":"Sarmiento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neus","family":"Canal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9858-3555","authenticated-orcid":false,"given":"Jorge","family":"Maurino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cort\u00e9s-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"issue":"12","key":"821_CR1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179742","volume":"134","author":"HJ Kaminski","year":"2024","unstructured":"Kaminski HJ, Sikorski P, Coronel SI, Kusner LL. Myasthenia gravis: the future is here. J Clin Investig. 2024;134(12): e179742. https:\/\/doi.org\/10.1172\/JCI179742.","journal-title":"J Clin Investig"},{"issue":"11","key":"821_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11): 2235. https:\/\/doi.org\/10.3390\/jcm10112235.","journal-title":"J Clin Med"},{"issue":"3","key":"821_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.medcli.2023.04.006","volume":"161","author":"DA Garc\u00eda Est\u00e9vez","year":"2023","unstructured":"Garc\u00eda Est\u00e9vez DA, Pardo Fern\u00e1ndez J. Myasthenia gravis. Update on diagnosis and therapy. Med Clin (Barc). 2023;161(3):119\u201327. https:\/\/doi.org\/10.1016\/j.medcli.2023.04.006.","journal-title":"Med Clin (Barc)"},{"issue":"3","key":"821_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-12922-7","volume":"272","author":"SNM Binks","year":"2025","unstructured":"Binks SNM, Morse IM, Ashraghi M, et al. Myasthenia gravis in 2025: five new things and four hopes for the future. J Neurol. 2025;272(3): 226. https:\/\/doi.org\/10.1007\/s00415-025-12922-7.","journal-title":"J Neurol"},{"key":"821_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00604","volume":"11","author":"ME Farrugia","year":"2020","unstructured":"Farrugia ME, Goodfellow JA. A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature. Front Neurol. 2020;11: 604. https:\/\/doi.org\/10.3389\/fneur.2020.00604.","journal-title":"Front Neurol"},{"issue":"5","key":"821_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16229","volume":"31","author":"NE Gilhus","year":"2024","unstructured":"Gilhus NE, Andersen H, Andersen LK, et al. Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment. Eur J Neurol. 2024;31(5): e16229. https:\/\/doi.org\/10.1111\/ene.16229.","journal-title":"Eur J Neurol"},{"issue":"1","key":"821_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/mus.27966","volume":"69","author":"MK Hehir","year":"2024","unstructured":"Hehir MK, Conaway M, St Sauveur AB, et al. Measuring treatment adverse event burden in myasthenia gravis: single-center prospective evaluation utilizing the Adverse Event Unit (AEU). Muscle Nerve. 2024;69(1):32\u20139. https:\/\/doi.org\/10.1002\/mus.27966.","journal-title":"Muscle Nerve"},{"issue":"5","key":"821_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/WCO.0000000000001196","volume":"36","author":"F Vanoli","year":"2023","unstructured":"Vanoli F, Mantegazza R. Current drug treatment of myasthenia gravis. Curr Opin Neurol. 2023;36(5):410\u20135. https:\/\/doi.org\/10.1097\/WCO.0000000000001196.","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"821_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","volume":"39","author":"L Gerischer","year":"2025","unstructured":"Gerischer L, Doksani P, Hoffmann S, Meisel A. New and emerging biological therapies for myasthenia gravis: a focussed review for clinical decision-making. BioDrugs. 2025;39(2):185\u2013213. https:\/\/doi.org\/10.1007\/s40259-024-00701-1.","journal-title":"BioDrugs"},{"issue":"23","key":"821_CR10","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1056\/NEJMoa2501561","volume":"392","author":"RJ Nowak","year":"2025","unstructured":"Nowak RJ, Benatar M, Ciafaloni E, et al. A phase 3 trial of inebilizumab in generalized myasthenia gravis. N Engl J Med. 2025;392(23):2309\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2501561.","journal-title":"N Engl J Med"},{"key":"821_CR11","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A, et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023;16:17562864231213240. https:\/\/doi.org\/10.1177\/17562864231213240.","journal-title":"Ther Adv Neurol Disord"},{"issue":"12","key":"821_CR12","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1007\/s10072-024-07577-7","volume":"45","author":"R Mantegazza","year":"2024","unstructured":"Mantegazza R, Sacc\u00e0 F, Antonini G, et al. Therapeutic challenges and unmet needs in the management of myasthenia gravis: an Italian expert opinion. Neurol Sci. 2024;45(12):5671\u201383. https:\/\/doi.org\/10.1007\/s10072-024-07577-7.","journal-title":"Neurol Sci"},{"issue":"4","key":"821_CR13","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s13760-024-02552-7","volume":"124","author":"JL De Bleecker","year":"2024","unstructured":"De Bleecker JL, Remiche G, Alonso-Jim\u00e9nez A, et al. Recommendations for the management of myasthenia gravis in Belgium. Acta Neurol Belg. 2024;124(4):1371\u201383. https:\/\/doi.org\/10.1007\/s13760-024-02552-7.","journal-title":"Acta Neurol Belg"},{"key":"821_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rare.2024.100051","volume":"3","author":"E Cort\u00e9s-Vicente","year":"2025","unstructured":"Cort\u00e9s-Vicente E, Hern\u00e1ndez R, Mart\u00ednez E, et al. Consensus recommendation for the treatment of generalised myasthenia gravis with anti-acetylcholine receptor antibodies in Spain. Rare. 2025;3:1\u20138.","journal-title":"Rare"},{"key":"821_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000211912","author":"S Thawani","year":"2025","unstructured":"Thawani S, Greenberg J, Tong S, et al. Management of myasthenia gravis around the globe: consensus guidelines versus realities of practice (P1\u201311.030). Neurology. 2025. https:\/\/doi.org\/10.1212\/WNL.0000000000211912.","journal-title":"Neurology"},{"issue":"4","key":"821_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/mus.28038","volume":"69","author":"KG Gwathmey","year":"2024","unstructured":"Gwathmey KG, Ding H, Hehir M, Silvestri N. How should newer therapeutic agents be incorporated into the treatment of patients with myasthenia gravis? Muscle Nerve. 2024;69(4):389\u201396. https:\/\/doi.org\/10.1002\/mus.28038.","journal-title":"Muscle Nerve"},{"issue":"4","key":"821_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0322168","volume":"20","author":"G Guti\u00e9rrez-Guti\u00e9rrez","year":"2025","unstructured":"Guti\u00e9rrez-Guti\u00e9rrez G, G\u00f3mez-Ballesteros R, Sotoca J, et al. Assessing therapeutic decisions in generalized myasthenia gravis: study protocol. PLoS ONE. 2025;20(4): e0322168. https:\/\/doi.org\/10.1371\/journal.pone.0322168.","journal-title":"PLoS ONE"},{"issue":"9","key":"821_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70081","volume":"7","author":"M Yung","year":"2024","unstructured":"Yung M, Narayanaswami P, Pesa J, et al. Patient and care partner perspectives and preferences related to myasthenia gravis treatment: a qualitative study. Health Sci Rep. 2024;7(9): e70081. https:\/\/doi.org\/10.1002\/hsr2.70081.","journal-title":"Health Sci Rep"},{"key":"821_CR19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000206306","author":"C Mansfield","year":"2024","unstructured":"Mansfield C, Ho KA, Pierce A, et al. Patient preferences for myasthenia gravis treatments: a discrete-choice experiment (P4\u201311.013). Neurology. 2024. https:\/\/doi.org\/10.1212\/WNL.0000000000206306.","journal-title":"Neurology"},{"key":"821_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00065","volume":"8","author":"G Saposnik","year":"2017","unstructured":"Saposnik G, Sempere AP, Prefasi D, et al. Decision-making in Multiple Sclerosis: the role of aversion to ambiguity for therapeutic inertia among neurologists (DIScUTIR MS). Front Neurol. 2017;8: 65. https:\/\/doi.org\/10.3389\/fneur.2017.00065.","journal-title":"Front Neurol"},{"issue":"2","key":"821_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12020274","volume":"12","author":"B Al-Omari","year":"2022","unstructured":"Al-Omari B, Farhat J, Ershaid M. Conjoint analysis: a research method to study patients\u2019 preferences and personalize care. J Pers Med. 2022;12(2): 274. https:\/\/doi.org\/10.3390\/jpm12020274.","journal-title":"J Pers Med"},{"issue":"7","key":"821_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16280","volume":"31","author":"A Meisel","year":"2024","unstructured":"Meisel A, Sacc\u00e0 F, Spillane J, Vissing J, MG Collegium Sub-committee. Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis. Eur J Neurol. 2024;31(7): e16280. https:\/\/doi.org\/10.1111\/ene.16280.","journal-title":"Eur J Neurol"},{"issue":"5","key":"821_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mus.22140","volume":"44","author":"S Muppidi","year":"2011","unstructured":"Muppidi S, Wolfe GI, Conaway M, Burns TM, MG Composite and MG-QOL15 Study Group. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011;44(5):727\u201331. https:\/\/doi.org\/10.1002\/mus.22140.","journal-title":"Muscle Nerve"},{"issue":"2","key":"821_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40120-025-00711-3","volume":"14","author":"A Ting","year":"2025","unstructured":"Ting A, Park M, Sangha O, Kumar M, Ricci JF, Lee E, et al. Risk of exacerbation and level of healthcare resource utilization in Myasthenia Gravis assessed by Myasthenia Gravis activities of daily living score. Neurol Ther. 2025;14(2):575\u201391. https:\/\/doi.org\/10.1007\/s40120-025-00711-3.","journal-title":"Neurol Ther"},{"issue":"1","key":"821_CR25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12911-021-01581-z","volume":"21","author":"Y Cho","year":"2021","unstructured":"Cho Y, Kim M, Choi M. Factors associated with nurses\u2019 user resistance to change of electronic health record systems. BMC Med Inform Decis Mak. 2021;21(1):218. https:\/\/doi.org\/10.1186\/s12911-021-01581-z.","journal-title":"BMC Med Inform Decis Mak"},{"key":"821_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.675520","volume":"12","author":"G Saposnik","year":"2021","unstructured":"Saposnik G, Bueno-Gil G, Sempere \u00c1P, et al. Regret and therapeutic decisions in multiple sclerosis care: literature review and research protocol. Front Neurol. 2021;12: 675520. https:\/\/doi.org\/10.3389\/fneur.2021.675520.","journal-title":"Front Neurol"},{"issue":"1","key":"821_CR27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12913-019-3889-4","volume":"19","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, M\u00e9ndez SJ, Scott A. Factors affecting general practitioners\u2019 decisions to adopt new prescription drugs - cohort analyses using Australian longitudinal physician survey data. BMC Health Serv Res. 2019;19(1):94. https:\/\/doi.org\/10.1186\/s12913-019-3889-4.","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"821_CR28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10459-018-9839-9","volume":"23","author":"M Hojat","year":"2018","unstructured":"Hojat M, DeSantis J, Shannon SC, et al. The Jefferson scale of empathy: a nationwide study of measurement properties, underlying components, latent variable structure, and national norms in medical students. Adv Health Sci Educ Theory Pract. 2018;23(5):899\u2013920. https:\/\/doi.org\/10.1007\/s10459-018-9839-9.","journal-title":"Adv Health Sci Educ Theory Pract"},{"issue":"5","key":"821_CR29","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s11606-014-3112-6","volume":"30","author":"ED Dolan","year":"2015","unstructured":"Dolan ED, Mohr D, Lempa M, et al. Using a single item to measure burnout in primary care staff: a psychometric evaluation. J Gen Intern Med. 2015;30(5):582\u20137. https:\/\/doi.org\/10.1007\/s11606-014-3112-6.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"821_CR30","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1177\/0013164405282471","volume":"66","author":"WB Schaufeli","year":"2006","unstructured":"Schaufeli WB, Bakker AB, Salanova M. The measurement of work engagement with a short questionnaire. Educ Psychol Meas. 2006;66(4):701\u201316.","journal-title":"Educ Psychol Meas"},{"issue":"1","key":"821_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jrp.2006.02.001","volume":"41","author":"B Rammstedt","year":"2007","unstructured":"Rammstedt B, John OP. Measuring personality in one minute or less: a 10-item short version of the big five inventory in English and German. J Res Pers. 2007;41(1):203\u201312.","journal-title":"J Res Pers"},{"issue":"6","key":"821_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16180","volume":"31","author":"F Sacc\u00e0","year":"2024","unstructured":"Sacc\u00e0 F, Salort-Campana E, Jacob S, et al. Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy. Eur J Neurol. 2024;31(6): e16180. https:\/\/doi.org\/10.1111\/ene.16180.","journal-title":"Eur J Neurol"},{"issue":"1","key":"821_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40120-022-00408-x","volume":"12","author":"K Jackson","year":"2023","unstructured":"Jackson K, Parthan A, Lauher-Charest M, et al. Understanding the symptom burden and impact of myasthenia gravis from the patient\u2019s perspective: a qualitative study. Neurol Ther. 2023;12(1):107\u201328. https:\/\/doi.org\/10.1007\/s40120-022-00408-x.","journal-title":"Neurol Ther"},{"issue":"6","key":"821_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16367","volume":"9","author":"G Antonini","year":"2023","unstructured":"Antonini G, Habetswallner F, Inghilleri M, et al. Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy. Heliyon. 2023;9(6): e16367. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16367.","journal-title":"Heliyon"},{"issue":"1","key":"821_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-024-03553-y","volume":"24","author":"J McCallion","year":"2024","unstructured":"McCallion J, Borsi A, Noel W, et al. Systematic review of the patient burden of generalised myasthenia gravis in Europe, the Middle East, and Africa. BMC Neurol. 2024;24(1): 61. https:\/\/doi.org\/10.1186\/s12883-024-03553-y.","journal-title":"BMC Neurol"},{"key":"821_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.vhri.2022.04.001","volume":"31","author":"JI Rojas","year":"2022","unstructured":"Rojas JI, Patrucco L, Alonso R, et al. Preferences for disease-modifying therapies in Argentina: cross-sectional conjoint analysis of patients and neurologists. Value Health Reg Issues. 2022;31:93\u2013100. https:\/\/doi.org\/10.1016\/j.vhri.2022.04.001.","journal-title":"Value Health Reg Issues"},{"key":"821_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105732","volume":"88","author":"N T\u00e9llez-Lara","year":"2024","unstructured":"T\u00e9llez-Lara N, G\u00f3mez-Ballesteros R, Sep\u00falveda M, et al. Preferences for neuromyelitis optica spectrum disorder treatments: a conjoint analysis with neurologists in Spain. Mult Scler Relat Disord. 2024;88: 105732. https:\/\/doi.org\/10.1016\/j.msard.2024.105732.","journal-title":"Mult Scler Relat Disord"},{"key":"821_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf288","author":"S Morishita","year":"2025","unstructured":"Morishita S, Sada KE, Kudo M, et al. Association of physicians\u2019 Big Five personality traits with shared decision-making in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2025. https:\/\/doi.org\/10.1093\/rheumatology\/keaf288.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"821_CR39","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s40120-022-00366-4","volume":"11","author":"G Saposnik","year":"2022","unstructured":"Saposnik G, Camacho A, D\u00edaz-Ab\u00f3s P, et al. Therapeutic decision-making under uncertainty in the management of spinal muscular atrophy: results from DECISIONS-SMA study. Neurol Ther. 2022;11(3):1209\u201319. https:\/\/doi.org\/10.1007\/s40120-022-00366-4.","journal-title":"Neurol Ther"},{"key":"821_CR40","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.2147\/NDT.S524459","volume":"21","author":"E Monreal","year":"2025","unstructured":"Monreal E, G\u00f3mez-Ballesteros R, Meca-Lallana V, et al. Neurologists\u2019 openness to evidence-based innovation in multiple sclerosis care: individual and structural determinants. Neuropsychiatr Dis Treat. 2025;21:1523\u201331. https:\/\/doi.org\/10.2147\/NDT.S524459.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"12","key":"821_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277474","volume":"17","author":"J von Knorring","year":"2022","unstructured":"von Knorring J, Lehti A, Fahlstr\u00f6m M, et al. Empathy as a silent art-a doctor\u00b4s daily balancing act: a qualitative study of senior doctors\u2019 experiences of empathy. PLoS ONE. 2022;17(12): e0277474. https:\/\/doi.org\/10.1371\/journal.pone.0277474.","journal-title":"PLoS ONE"},{"issue":"1","key":"821_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-57825-1","volume":"14","author":"A Anderson","year":"2024","unstructured":"Anderson A, Pesa J, Choudhry Z, et al. Patient perceptions of disease burden and treatment of myasthenia gravis based on sentiment analysis of digital conversations. Sci Rep. 2024;14(1): 7271. https:\/\/doi.org\/10.1038\/s41598-024-57825-1.","journal-title":"Sci Rep"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00821-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00821-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00821-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:45:24Z","timestamp":1763376324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00821-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["821"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00821-y","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Luis Querol reports receiving speaker honoraria from Merck, Sanofi, Roche, Biogen, Grifols, and CSL Behring; providing expert testimony for Grifols, Johnson & Johnson, Annexon Pharmaceuticals, Sanofi, Novartis, Takeda, and CSL-Behring; and receiving research funds from Roche, UCB, and Grifols. Gerardo Guti\u00e9rrez-Guti\u00e9rrez reports receiving consulting fees from CSL Behring, Biogen, Alter, Takeda, Akcea, Lupin Neuroscience, Roche, Alexion, and Argenx; congress support from Alter, Esteve, Sanofi-Genzyme, Pfizer, and UCB Pharma; scientific collaborations with Lilly, Alexion, Genzyme, Takeda, Biogen, Pfizer, and Alter; royalties from books published with Exeltis, Alter, Esteve, Andr\u00f3maco, and Bristol-Myers; and grants and awards from Lilly, UCB Pharma, and CSL Behring. Adri\u00e1n Ares reports receiving speaking honoraria, consultation fees, or travel support for congress and scientific meetings attendance from Almirall, Bayer, Biogen, BMS, Janssen, Merck, Novartis, Roche, Sanofi, and Teva. Elena Cort\u00e9s-Vicente reports consulting or advisory relationships with UCB Pharma SA, Janssen Pharmaceuticals Inc, Alexion Pharmaceuticals Inc, Argenx, and Lundbeck. M\u00f2nica Sarmiento, Neus Canal, and Pablo Rebollo are employees of IQVIA Spain, the contract research organization that conducted this study for Roche. Roc\u00edo G\u00f3mez-Ballesteros, Paola D\u00edaz-Ab\u00f3s, Elisa Salas, and Jorge Maurino are employees of Roche Farma Spain. Ram\u00f3n Villaverde, Virginia Reyes, and Tha\u00eds Armangu\u00e9 declare no conflicts of interest for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the institutional review board of Hospital Cl\u00ednico Universitario San Carlos (Madrid, Spain).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}